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Abstact 
The present review represents a concise and complete survey of the literature covering  2004-2009, concerning the mass 
spectrometric techniques involved in the structural investigation of renal calculi. After a short presentation of the fundamental mass 
spectrometric techniques (MALDI-TOF, QTOF, MS-MS) as well as hyphenated methods (GC-MS, LC-MS, CE-MS), an extensive 
study of the urinary proteome analysis as well as the detection and quantification by mass spectrometry of toxins, drugs and 
metabolites from renal calculi is presented.  
Introduction 
Over the past decade, progress in mass 
spectrometry and its hyphenation with the separation 
techniques has made these tools essential in life 
sciences. The use of MS is, however, not yet a routine in 
many fields where it could influence clinical decisions. 
While medical research using MS is flourishing, few 
applications have become part of the standard “bedside” 
practice. This is partly because the transition of MS from a 
research tool to a reliable clinical diagnostic platform 
requires rigorous standardization, spectral quality control 
and assurance, standard operating procedures for robotic 
and automatic sample application, and standardized 
controls to ensure the generation of highly reproducible 
spectra [1]. In a previous review, we focused on 
contribution of mass spectrometry in finding and 
characterizing the protein biomarkers [2]. In this review, 
we provide an overview of new developments in mass 
spectrometry methods, cover the most promising 
technical aspects of different approaches to renal calculi 
analysis (2005-2010), and examine the inherent technical 
advantages and limitations. 
Fundamentals of mass spectrometry 
Mass spectrometry is a sensitive analytical 
technique, which is able to quantify known analytes and to 
identify unknown molecules at the picomoles or 
femtomoles level. A mass spectrometer is an instrument, 
which volatilizes and ionizes molecules and measures, 
more precisely ion abundance, as a function of the ionic 
mass-to-charge ratio. (Figure 1) Mass spectrometers are 
unable to detect neutral molecules and radicals [3]. 
Typically, a mass spectrometer is made up of the 
following components: 
(a)  a source to produce ions  
(b)  one or several mass analyzers,  
(c)  a detector to measure the abundance of ions  
 
 
 
 
 
 
 
 
Fig. 1 Principle of a mass spectrometer 
 
Ion Sources  
The analyzed samples in the ion sources are 
ionized prior to analysis in the mass spectrometer. 
Depending on the nature of the ionization process, and 
also on the nature of the atoms and molecules 
themselves, positive and negative ion types can be 
formed [3,4]. Some ionization techniques are very 
energetic and cause extensive fragmentation. Other 
techniques are softer and only produce ions of molecular 
species. Ion sources exist under two types: liquid-phase 
ion sources and solid-state ion sources [5]. 
  (1) In liquid-phase ion sources, the analyte is in 
solution. This solution is introduced, by nebulization, as 
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droplets into the source, where ions are produced at an 
atmospheric pressure and focused into the mass 
spectrometer through some vacuum pumping stages. 
Electrospray (ESI), atmospheric pressure chemical 
ionization (APCI) and atmospheric pressure 
photoionization (APP) sources correspond to this type. 
(2) In solid-state ion sources, the analyte is in an 
involatile deposit. This deposit is then irradiated by 
energetic particles or photons that desorb ions near the 
surface of the deposit. These ions can be extracted by an 
electric field and focused towards the analyser. Matrix-
assisted laser desorption (MALDI), surface-enhanced 
laser desorption/ionization (SELDI), secondary ion mass 
spectrometry (SIMS), plasma desorption (PD) and field 
desorption (FD) sources all use this strategy to produce 
ions. Fast atom bombardment (FAB) uses an involatile 
liquid matrix. The ion sources produce ions mainly by 
ionizing a neutral molecule in the gas phase through 
electron ejection, electron capture, protonation, 
deprotonation, adduct formation or by the transfer of a 
charged species from a condensed phase to the gas 
phase. 
 
Mass analyzers 
All mass analyzers perform a separation of ions 
according to their m/z The simplest way of ion separation 
is just to let them fly and measure their time of flight. This 
type of analyzer is called time of flight (TOF). Here, 
electrostatic potential gradients are used to 
accelerate/decelerate the ions. Another way to ion 
separation is achieved by the interaction of ions with an 
electrostatic (electric sector analyzer, ESA or orbitrap 
(OT)) or a magnetostatic (magnet, B) field. A resonant 
electromagnetic field is applied in quadrupoles (Q), and 
three-dimensional or linear ion traps (3D-IT and LTQ, 
respectively). A combination of electric (E) and magnetic 
(B) fields is used in Fourier transform ion cyclotron 
resonance (FTICR) instruments and also the technique of 
accelerator mass spectrometry (AMS) [5,6]. Tandem 
mass spectrometry (MS/MS) is a technique where 
structural information on sample molecules is obtained by 
using multiple stages of mass selection and mass 
separation. Tandem mass spectrometry requires the 
fragmentation of the precursor ion selected by the first 
analyzer in order to allow the second analyzer to analyze 
the product ions. This can be achieved by collisional 
activation via collisions of (selected) ion with neutral gas 
molecules (collision-induced dissociation, CID). CID is a 
two-step process: ion translational energy is converted 
into ion internal energy in the collision event, and 
subsequently unimolecular decomposition of the excited 
ion may yield various product ions [5-7].  Two stages of 
mass analysis are required: one to select the precursor 
ion from other ions generated in the ion source, and one 
to analyze the product ions after the collisions (Figure 2).  
 
 
 
 
Fig. 2 Principle of tandem mass spectrometry (MS/MS) 
 
Detector  
Modern mass spectrometers are equipped with 
detectors of great sensitivity. The detectors most 
commonly used include the electron multiplier, the 
photomultiplier, the conversion dynode, the Faraday cap, 
the array detector, and the charge or inductive detector. 
From the operational point of view, reliable vacuum 
systems are a prerequisite for mass spectral 
measurements [7,8]. 
The final step of a mass spectral analysis is the 
recording of the mass spectrum by detecting the ions 
after their separation. The mass spectrum is a unique 
characteristic of a compound. In general, it contains 
information on the molecular mass of an analyte 
(molecular ion) and the masses of its structural fragments. 
 
Hyphenated methods 
In order to analyze a complex mixture, for 
example natural products, a separation technique – gas 
chromatography (GC), liquid chromatography (LC) or 
capillary electrophoresis (CE) – is coupled with the mass 
spectrometer. The separated products must be introduced 
one after the other into the spectrometer, either in the 
gaseous state for GC-MS, or in solution for LC-MS and 
CE-MS. This can occur in two ways: the eluting 
compound is collected and analyzed off-line; or the 
chromatograph is directly connected to the mass 
spectrometer and the mass spectra are acquired while the 
compounds of the mixture are eluted. The latter method 
operates  on-line. The most obvious advantage drawn 
from the coupling of a separation technique with a mass 
spectrometry consists in obtaining a spectrum used in 
identifying the isolated product and evaluating the 
components quantitatively [6,8]. 
Mass spectrometry in Urinary Proteome 
Analysis 
Proteome research related to nephrology has 
generally focused on the examination of urine because it 
is easily accessible in a large quantity without the use of 
invasive procedures. Furthermore, as a rule, 
pathophysiologic changes in the genitourinary tract and 
the kidney are reflected by changes in the urinary 
proteome [9]. Although many studies have shown that 
proteins in biologic fluids may degrade rapidly when 
handled inappropriately, urinary proteins have been 
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shown to remain stable long enough to perform reliable 
proteome analysis [10]. The reliable identification of 
protein expression patterns in various renal calculi that 
differentiate the diseased kidneys from the healthy ones 
or those that distinguish between different stages of a 
disease have now started to become feasible. 
Proteomic analysis of renal calculi indicates an 
important role for inflammatory processes in calcium 
stone formation. Lederer and all [11] analyzed isolated 
renal stone matrix proteins with 1D RPLC-MS, MALDI-
TOF MS and immunohistochemical methods identifying 
158 proteins with high confidence, including 28 common 
proteins. Several investigators have examined the protein 
content of CaOx stones, identifying proteins either coating 
the crystals or embedded in the stones’ crystalline 
structure, such as OPN, THP, and urinary PF1. The 
significance of these differences in protein association 
with stones and their roles in inhibition, promotion, or 
reaction to stone formation, while heavily investigated, 
remain to be thoroughly defined. In addition to the 
contribution of constitutive urinary proteins, the elicited 
inflammatory responses may further contribute to the 
proteomic milieu. These proteins, whether from cellular 
compartments of the kidney or from filtered serum 
proteins, will all likely contribute to the composition of the 
stone proteome. The results of the group identified 
previously, unreported stone matrix proteins (SMP), some 
of which may be involved in critical elements of stone 
formation. In conclusion, the proteomic analysis of a 
limited set of renal stones has significantly expanded the 
list of known SMP. The diverse origin of these proteins 
(i.e., extracellular, intracellular, membrane proteins) 
attests a complex and multifactorial pathogenesis of stone 
formation. The data do not provide discrete mechanistic 
information regarding the stones’ formation. Indeed, a 
possible significant portion of the identified SMP may be 
derived from the cellular damage resulting from stone 
growth and may not involve directly with stone growth per 
se [11]. 
It is known that urinary calculi are often 
complicated in patients with gout, hyperuricemia, or 
hypouricemia. In order to examine the growth mechanism 
of urinary calculi in these patients and to prevent 
recurrence of calculi, it is important to carefully analyze 
each patient’s individual pathological calculus. Although 
not generally known, several proteins, collectively dubbed 
‘‘the matrix,’’ have been reported as organic components 
in renal stones (first, albumin then α-globulins and γ-
globulins followed). Protein Z, a vitamin K-dependent 
plasma protein, has been firstly detected in a renal 
calculus, along with osteopontin and prothrombin, by 
Fujimori group [12]. The renal calculus was obtained from 
a hyperuricemic patient. Several proteins from the renal 
calculus, which have migrated in 2D-PAGE, were excised 
from the gel, digested with trypsin in gel, and then applied 
to LC-MS.  The proteins from each isolated spot in 2D gel 
were analyzed by tandem mass spectrometry; many 
MS/MS spectra were obtained. The computerized protein 
identification program, SEQUEST, a tandem mass 
spectrum database-matching tool, was applied. Three 
proteins, osteopontin, prothrombin, and protein Z, were 
identified in this renal stone. The spectrometer was 
equipped with a nanoelectrospray interface and an ion 
trap. Four peptides were determined from  protein  Z (the 
positions were 203–215, 232–240, 320–327, and 413–
418 amino acids, respectively) in the calculus, through 
LC-MS/MS analysis. Authentic protein Z was also 
analyzed by using the same method, and all four peptides 
determined in the calculus were similarly identified. 
Whereas protein Z has been reported to be one of the 
vitamin K-dependent calcium-binding proteins, its role has 
not been well established yet. Because the physiological 
role of protein Z is hardly understood, the fact that it has 
been identified in a renal calculus is of great interest. This 
finding should prove helpful in any future examination of 
the role of protein Z in the body and the lithic generation 
mechanism in patients with urolithiasis.[12]. 
The kidney stone formation is a complex process 
involving multiple factors. Kidney stones invariably 
comprise a combination of inorganic crystals and organic 
macromolecules consisting principally of proteins. Many 
proteins occur in stones, but their role in urolithiasis 
remains unknown. Calculi contain some proteins normally 
present in urine, in addition to others arising from injury 
inflicted by the stones themselves, making it impossible to 
discriminate between those that bind to the stone as it 
grows, but play no role in its development, and those that 
may be involved in regulating the formation of stone 
crystals. Tandon and his coworkers were able to 
fractionate renal stone matrix proteins, to purify most 
potent antilithiatic protein, to study its effect on calcium 
oxalate crystal growth system and to characterize them by 
using mass spectrometry [13]. Proteins having MW>10 
kDa were subjected to anion exchange and molecular-
sieve chromatography. Protein fractions were tested for 
their effects on CaOx crystal growth. Most potent fraction 
P2′ was excised, in-gel tryptic digested and identified by 
matrix assisted laser desorption/ionization-time of flight 
(MALDI-TOF) MS. As a result, an anionic protein (MW~42 
kDa) with potent inhibitory activity against CaOx crystal 
growth was purified. Its homogeneity was confirmed by 
RP-HPLC. It was identified by MALDI-TOF-MS followed 
by database search on MASCOT server as human 
phosphate cytidylyltransferase 1, beta. The molecular 
weight of this novel CaOx crystal growth inhibitor, from 
human renal stone matrix, is also the same as that of 
human phosphate cytidylyltransferase 1, choline [13]. 
Of all types of renal stones, calcium oxalate 
(CaOx) is the most common composition found by 
chemical analysis. Up until present, the pathogenic 
mechanisms of stone formation remain unclear. One long-
standing hypothesis is that stone formation is related to 
intratubular crystal nucleation, growth, and aggregation. 
The urine from patients with nephrolithiasis is commonly 
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supersaturated with calcium and oxalate ions, favoring 
CaOx crystal nucleation and growth.  Additionally, there 
are urinary substances known as “stone inhibitors” in the 
normal renal tubular fluid that inhibit intratubular crystal 
growth, aggregation, and/or adhesion to renal epithelial 
surfaces. These substances include proteins, lipids, 
glycosaminoglycans, and inorganic compounds. 
Abnormality in function and/or expression levels of these 
molecules, especially proteins, in the urine and renal 
tubular fluid has been proposed to be associated with 
stone formation. The identification of additional stone 
inhibitors would increase the understanding of the 
pathogenesis and pathophysiology of nephrolithiasis. 
Thongboonkerd and his coworker [14] have combined 
conventional biochemical methods with recent advances 
in mass spectrometry (MS) to identify a novel calcium 
oxalate (CaOx) crystal growth inhibitor in normal human 
urine. Anionic proteins were isolated by DEAE adsorption 
and separated by HiLoad 16/60 Superdex 75 gel filtration. 
A fraction with potent inhibitory activity against CaOx 
crystal growth was isolated and purified by anion 
exchange chromatography. The protein in two 
subfractions that retained inhibitory activity was identified 
by MS (MALDI-TOF) matrix-assisted laser 
desorption/ionization–time-of-flight and MS (ESI-QTOF-
MS/MS) electrospray ionization–quadrupole–time-of-flight 
tandem, as human trefoil factor 1 (TFF1). Western blot 
analysis confirmed the mass spectrometric protein 
identification. Functional studies of urinary TFF1 
demonstrated that its inhibitory potency was similar to that 
of nephrocalcin. The inhibitory activity of urinary TFF1 
was dosed dependently and was inhibited by TFF1 
antisera. Anti–C-terminal antibody was particularly 
effective, consistent with proposed model, in which the 4 
C-terminal glutamic residues of TFF1, interact with 
calcium ions to prevent CaOx crystal growth. 
Concentrations and relative amounts of TFF1 in the urine 
of patients with idiopathic CaOx kidney stone were 
significantly less (2.5-fold for the concentrations and 5- to 
22-fold for the relative amounts) than those found in 
controls. These data indicate that TFF1 is a novel potent 
CaOx crystal growth inhibitor with a potential 
pathophysiological role in nephrolithiasis [14] 
Adult human urine is often supersaturated with 
calcium and oxalate ions, which can lead to the 
precipitation of calcium oxalate (CaOx) crystals thereby 
making individuals prone to stone formation. Proteins are 
found as a major component in the matrix and organic 
matrix and are considered to have a potential role in stone 
formation, growth and crystal-membrane interaction. 
Proteins, which have crystal binding affinity, could play a 
critical role in the mediation of the earliest events in 
kidney stone formation. Shafqat and his group [15] 
characterized proteins from the inner core and outer 
matrix of calcium oxalate (CaOx) renal stones, in order to 
understand the mechanism of stone genesis. Inner core 
and outer matrix of CaOx renal stones were separated 
and proteins were extracted with a buffer containing SDS 
and β-mercaptoethanol. The proteins were analyzed and 
purified by SDS-PAGE and RP-HPLC respectively. The 
protein bands from gel and protein fractions were 
sequenced by MALDI TOF mass spectrometry. ELISA, 
western and slot blot immunoassays were performed to 
confirm the identity of the proteins in stones and urine of 
the stone formers. The potential of the identified protein 
as an effective promoter or inhibitor was assessed by 
observing their effects on CaOx crystallization by using an 
aggregometer. The inner core extract predominantly 
exhibited protein species in the molecular weight range of 
12–14 kDa. However, a 66 kDa band, identified as 
osteopontin was also detected in the inner core along with 
outer matrix and in the urine of stone formers and non 
stone formers. The purification of low molecular weight 
proteins was carried out by reversed phase HPLC. 
Tandem mass spectrometry analysis identified them as 
myeloperoxidase chain A (MPO-A), α-defensin, and 
calgranulin. ELISA, western blot and slot-blot immuno-
assays further confirmed their presence restricted to the 
inner core and not in the outer matrix. Turbidity assays 
showed that low molecular weight renal stone proteins 
promoted the aggregation of CaOx crystals. From these 
results, the author concluded that persistent hyperoxaluria 
leads to tubular epithelial injury, resulting in the release of 
these anti-inflammatory proteins. These proteins could 
have been firstly adsorbed on CaOx crystals, so, they 
became a part of nucleation process leading to inner 
matrix formation [15]. 
OPN (osteopontin) is a highly phosphorylated 
glycoprotein present in many tissues and body fluids. In 
urine, OPN is a potent inhibitor of nucleation, growth and 
aggregation of calcium oxalate crystals, suggesting that it 
has a role in the prevention of renal stone formation. The 
role of OPN in nephrolithiasis is, however, somewhat 
unclear, as it may also be involved in urinary stone 
formation, and it has been identified among the major 
protein components of renal calculi. Most likely, the 
function of OPN in urine is dependent on the highly 
anionic character of the protein. Besides a very high 
content of aspartic and glutamic residues, OPN is 
subjected to significant PTM (posttranslational 
modification), such as phosphorylation, sulfation and 
glycosylation, which may function as regulatory switches 
in promotion or inhibition of mineralization. Sorensen & all 
[16] have characterized the PTMs of intact human urinary 
OPN and N-terminal fragments thereof. Urine samples 
from seven healthy donors, with normal renal function and 
no history of urinary disease, were analyzed by Western 
blotting, to examine the molecular forms of OPN in urine. 
OPN was purified from human urine by anion exchange 
followed by RP-HPLC separation. The sequencing of the 
OPN-containing fraction showed two sequences: a major, 
and a minor one, both corresponding to the N-terminal 
part of human OPN. SDS/PAGE revealed the presence of 
three bands migrating at approx. 45 (OPN45), 50 
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(OPN50) and 60 kDa (OPN60) respectively, and Western 
blotting confirmed their OPN nature. The masses of the 
OPNs were determined by linear MALDI–TOF-MS. MS 
analysis showed a mass of approx. 37.7 kDa for OPN60, 
whereas the sample containing OPN45 and OPN50 
showed one broad mass peak with an average value of 
approx. 29.3 kDa. In order to estimate the total number of 
phosphate groups present, OPN60 and the fragments 
OPN45/OPN50 were treated with ALP. The molecular 
mass of dephosphorylated OPN60 was of 37.1 kDa, 
corresponding to a loss of approximately eight phosphate 
groups. Phosphatase treatment of the N-terminal OPN 
fragments, reduced the mass to 28.8 kDa, corresponding 
to a loss of approximately six phosphorylations. The 
subtraction of the theoretical mass of the human OPN 
polypeptide (33714 Da) from the observed average mass 
of dephosphorylated OPN60 (37.1 kDa), leaves approx. 
3.4 kDa, which means that the other PTMs must be 
accounted for. In addition, one sulfated tyrosine and five 
O-linked glycosylations were identified in OPN, whereas 
no N-linked glycans were detected. Peptide mapping and 
immunoblotting using different monoclonal antibodies 
showed that the N-terminal fragments present in urine are 
generated by proteolytic cleavage at Arg228–Leu229 and 
Tyr230–Lys231[16] 
The interaction between crystals and renal 
tubular cells has been proposed to be a crucial event that 
elicits subsequent cellular responses, leading to kidney 
stone formation. Nevertheless, the molecular mechanisms 
of these cellular responses remain poorly understood. 
Thongboonkerd  and coworkers [17] performed a gel-
based differential proteomics study to examine cellular 
responses (as determined by altered protein expression) 
in Madin-Darby canine kidney (MDCK) cells, which were 
derived from dog kidney and exhibited distal renal tubule 
phenotype, during calcium oxalate dehydrate (COD) 
crystal adhesion. MDCK cells were grown in a medium 
with or without COD crystals (100 μg/ml) for 48 h. Crystal 
adhesion was illustrated by phase-contrast and scanning 
electron microscopy (SEM). Flow cytometry using annexin 
V/propidium double staining iodide showed that the 
percentage of cell death did not significantly differ 
between cells with and without COD crystal adhesion. 
Cellular proteins were then extracted, resolved with two-
dimensional gel electrophoresis (2-DE), and visualized by 
SYPRO Ruby staining (n ) 5 gels per group). Quantitative 
intensity analysis revealed 11 significantly altered 
proteins, 10 of which were successfully identified by 
quadrupole time-of-flight (Q-TOF-MS), peptide mass 
finger printing and/or tandem MS (MS/MS): Lamin B, 
Heterogeneous nuclear ribonucleoprotein H1, Cytokeratin 
7, Ornithine aminotransferase (OAT -mitochondrial 
precursor isoform), Branched -chain-amino-acid 
aminotransferase, Alcohol dehydrogenase (ADH), 
Annexin A2 (Anx II), Glyceraldehyde-3-phosphate 
dehydrogenase (G3PDH), Galactose-specific lectin. An 
increase in annexin II was confirmed by 2-D Western blot 
analysis. The data from their experiments may lead to 
better understanding of the cellular responses in distal 
renal tubular cells during COD crystal adhesion [17]. 
The matrix stones are rare calculi that present 
not as crystalline solids but as soft, proteinaceous 
material within the kidney collecting system. The converse 
of stone matrix and matrix stones have little minerals and 
they are primarily composed of organic material that could 
be ideal for protein extraction. They have been identified 
in patients with recurrent urinary tract infections and in 
proteinuric patients with glomerulonephritis and end-stage 
kidney disease on hemodialysis. In an attempt to 
understand the factors responsible for matrix stone 
formation, Canales & all [18] determined the mineral, 
topographical, and proteomic composition of a surgically 
extracted matrix stone using modern identification 
technology. Following wide-angle X-ray diffraction (XRD) 
and scanning electron microscopy (SEM), they 
homogenized a surgically removed matrix stone, 
extracted and purified protein, and analyzed samples by 
using tandem mass spectrometry for proteomic 
composition. Resulting spectra were searched by using 
ProteinPilot 2.0, and the identified proteins were reported 
with >95% confidence. Primary XRD mineral analysis was 
a biological apatite, and SEM revealed fibrous, net-like 
laminations containing bacterial, cellular, and crystalline 
material. Out of the 33 unique proteins identified (among 
them: Protein C, Prothrombin  Anti-TNFα-antibody, 
Calgranulin A, Calgranulin B, Cathepsin G, Ig light chain, 
IgG2 IgG heavy chain, Ig kappa light chain, Lactoferrin, 
Lysozyme C,Myeloblastin, Myeloperoxidase, Albumin, 
Histidine-rich glycoprotein, Plasminogen, Hemoglobin 
alpha chain, Hemoglobin beta chain), 90% have not been 
previously reported within matrix stones, and over 70% 
may be considered inflammatory or defensive in nature. 
The characterization of other matrix stone proteomes, in 
particular from non-infectious populations, may yield 
insights into the pathogenesis of this rare stone, as well 
as the mineralogical process that occurs within crystalline 
calculi [18]. 
Detection and quantification of toxins, 
drugs and metabolites from renal calculi, 
by mass spectrometry 
Oxalic acid is a major product of ascorbic acid 
oxidation, having the potential to crystallize like calcium 
oxalate in the urinary space. Huge oral doses of ascorbic 
acid modestly increase urinary oxalic acid excretion and 
could theoretically increase the risk of stone formation in 
susceptible people. The rate limitation of intestinal 
ascorbic acid transport makes it unlikely that the oral 
doses higher than 500 mg/d will increase oxalic acid 
excretion and stone risk, proportionately with the 
intravenous administration that bypasses this barrier. 
Hoffer & all [19] developed gas chromatography mass 
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spectrometry (GC-Q-MS) methodology, sampling and 
storage procedures for oxalic acid analysis without the 
interference of the ascorbic acid and measured urinary 
oxalic acid excretion, in people who were administered 
intravenous ascorbic acid in doses ranging from 0.2 to 1.5 
g/kg according to body weight. In vitro oxidation of the 
ascorbic acid to oxalic acid did not occur when urine 
samples were immediately brought to a pH level of less 
than 2 and stored at −30°C for 6 hours [19]. 
Several antiretroviral drugs such as nelfinavir, 
efavirenz and atazanavir have been presented to cause 
urinary stone [20-22]; Strebel & all [23] reported the first 
case of pro-lithogenic amprenavir - in a female with HIV 
infection - adding this to the growing list of antiretroviral 
drugs associated with urinary stones. The abdominal CT 
of the patient revealed three obstructing stones (of 
4x8mm; 2x1cm; 4 mm in diameter). Before undergoing an 
interventional treatment, one stone had passed 
spontaneously. The stone was analyzed by liquid 
chromatography with mass spectrometry (LC-MS). The 
analysis of the stone revealed a composition of 95% 
amprenavir and 5% ritonavir. It was the first time a report 
was made on a urinary stone composed of unmodified 
amprenavir [23]. 
An unprecedented epidemic of renal disease 
affecting children after the consumption of melamine-
tainted milk products (MTMP) was reported two years 
ago. The spectrum of this disease, its clinical features, 
and criteria, for laboratory diagnosis and monitoring, have 
not been very well defined. Urolithiasis is an uncommon 
condition in children and therefore, it was observed that 
this issue unexpectedly increased the incidence of urinary 
stones and renal failure in infants, in China, before 2008. 
The association between this disease and the exposure to 
MTMP has not yet been defined by epidemiological 
studies. Although melamine alone has a low animal 
toxicity and its being rapidly eliminated, unchanged after 
ingestion, led to the conclusion that it can form an 
insoluble complex with cyanuric acid, a structural 
analogue of melamine which often co-exists as either an 
impurity or metabolite, thereby causing crystalluria, kidney 
stones and nephrotoxicity. The pet foods were found to 
contain melamine and cyanuric acid in high 
concentrations, which were traced to wheat gluten and 
rice protein sourced from China. In addition, the diagnosis 
of melamine-associated renal stone disease (MARSD) is 
suspected due to the presence of urinary tract stones on 
ultrasound examination in patients exposed to MTMP. As 
melamine associated renal stones (MARS) can be 
spontaneously passed out of the urinary tract, Tam & all 
[24] developed a non-invasive method for the diagnosis 
and monitoring of MARSD patients. For the detection and 
quantification of urinary melamine, they used an ESI-TQ-
MS (triple–quadruple tandem mass spectrometer) 
operating in a positive mode with pneumatically assisted 
electrospray. A GC-MS (gas-chromatography mass-
spectrometer) was employed for the measurement of 
urinary cyanuric acid. They found a strong correlation 
between renal stone size and urinary melamine 
concentration. For stones with the diameter of less than 
10 mm, a 10 μg/mmol creatinine increase in the urinary 
melamine concentration is associated with the 
approximately 1 mm increase in the size of the stone. The 
high degree of the correlation strongly suggests that 
melamine is related to stone formation in humans. Using 
receiver operating characteristic analysis, they proposed 
that patients, who have a persistent melamine level above 
the optimal cut-off value of 7.1 μg melamine/mmol 
creatinine in urine, might have a significant exposure of 
melamine-tainted products. Unlike melamine, urinary 
cyanuric acid is not significantly different between cases 
and controls. Pathophysiological findings from feeding 
animals with melamine and cyanuric acid may not be 
directly applicable to humans. Finally, they found out that 
both melamine and urine metabolic lithogenic factors are 
important in the formation of melamine-related stones. 
Apart from aiding in the case screening and confirmation, 
the urine melamine level might as well be an indicator of 
residual melamine load in the body and thus, it is useful 
for the following-up and monitoring of the confirmed cases 
[24].  
The outbreak of food adulteration with melamine 
was firstly discovered in dairy products, and this 
adulterant is now found in other types of food products 
such as eggs and seafood. In 2007, pet food adulteration 
with melamine leading to kidney toxicity in cats and dogs 
was reported. It is believed that melamine per se is 
nontoxic. However, when it encounters cyanuric acid, an 
analogue of melamine, a stable compound (melamine 
cyanurate), as shown in Figure 3, a poor aqueous 
solubility is formed [25]. This compound precipitates in 
renal tubules, results in the formation of kidney stones, 
and eventually leads to renal toxicity. Matrix-assisted 
laser desorption/ionization mass spectrometry (MALDI-
MS) was applied by Che & colab. [26] to the direct 
analysis of melamine cyanurate (MC). The three 
commonly used MALDI matrixes, namely, cyano-4-
hydroxycinnamic acid (CHCA), sinapinic acid (SA), and 
2,5-dihydroxybenzoic acid (DHB), were able to 
desorb/ionize melamine from MC upon N2 laser 
irradiation, with CHCA showing the highest detection 
sensitivity in the positive mode. Only DHB and SA were 
able to desorb/ionize cyanuric acid from MC in the 
negative mode but with a remarkably lower sensitivity. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Chemical structure of melamine (1), cyanuric acid (2), 
and melamine cyanurate (3). 
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The urine matrix resulted in ion peaks interfering 
and it suppressed the ion intensity of melamine, while, a 
cleanup process consisting of a simple wash-up, 
eliminated such interference and enhanced the ion 
intensity. The procedure developed by the authors 
allowed the detection of melamine from a small amount of 
melamine cyanurate, down to as low as 12.5 μg in 1 mL 
of urine, and could be used for the screening analysis of 
urine residue samples. In combination with accurate mass 
measurement and tandem mass spectrometric analysis, 
the method could allow the confirmatory identification of 
the analyte. In terms of practical application, the method 
was first applied in the detection of melamine, from urine 
stone/residue samples, collected from patients clinically 
confirmed as having kidney stones associated with the 
consumption of melamine-tainted food products. The 
advantages of this method are the simplicity of sample 
preparation and the rapidity of MALDI-MS analysis. The 
analytical time per sample, is less than 7 min when the 
method is applied in a high-throughput manner. This 
method allows the specific detection of the chemical 
composition of solid urine stone/residue samples, and has 
a potential for use in the clinical diagnosis of other 
complex biological samples, in the solid state [26]. 
Uric acid (2,6,8-trihydroxypurine, UA) is the 
major nitrogenous compound in urine, but it is also found 
in other biological fluids such as serum, blood and saliva. 
Around 8% of renal calculi are formed by UA. It has also 
been demonstrated that a group of calcium oxalate 
monohydrate renal calculi have a core formed by 
important amounts of UA, which act as heterogeneous 
nucleant. In some cases, due to the little size of the core, 
or the presence of an abundant organic matter, the 
presence of uric acid cannot be confirmed, in spite of its 
importance to establish the calculus etiology, and, 
therefore, the most appropriate pharmacologic and/or 
dietetic treatment. Elevated levels of UA can be caused 
by many factors, including increased alcohol 
consumption, obesity, diabetes, high cholesterol, high 
blood pressure, kidney disease, and heart disease. UA is 
the main final product of purine metabolism and its 
determination in urine is a powerful indicator of metabolic 
alterations or disease appearance. Grases & all proposed 
[27] a very simple and direct method for the determination 
of uric acid, in various biological matrices, based on high-
performance liquid chromatography and mass 
spectrometry (HPLC-MS). Chromatographic separations 
were performed with a stationary phase Zorbax Sax 
Column, an anion exchange resin, with 50% sodium 
citrate 1mM at pH 6.5 and 50% acetonitrile, as a mobile 
phase delivered at a flow rate of 1 ml/min. The detector 
counted negative ions by monitoring m/z  167.1, which 
corresponds to the urate anion. The method does not use 
an internal standard but quality control samples were 
used. Recovery tests of added standard have been 
successfully performed in urine and saliva samples, thus 
showing an appropriate accuracy of the method. The limit 
of quantization found was of 70 _g/l. Different urine and 
saliva samples were analyzed and applied to the 
determination of trace amounts of uric acid in the core of 
some selected calcium oxalate renal calculi [27].  
Urinary stones may form anywhere in the renal 
tract and will often pass through in an uneventful fashion. 
Recurrence of stone disease is a problem and it is 
recognized that, without medical treatment, 50% of 
patients will form another stone within 10 years. The 
determination of citrate excretion is important in the 
investigation of patients with recurrent stone disease, 
because the formation of calcium-based stones, which 
accounts for 85% of all stones formed in the urinary tract, 
is known to be inhibited by citrate. Citrate in urine inhibits 
the formation of calcium salts by forming soluble 
complexes with calcium, and, hypocitraturia is associated 
with an increased risk of stone formation. Hypocitraturia, 
defined as a citrate excretion of <1700 mmol/24 h, is 
found in renal tubular acidosis, chronic diarrhea, chronic 
diuretic use and chronic dehydration. In these situations, 
supplementation with potassium citrate is the best 
treatment, either as effervescent or wax-coated tablets. 
The measurement of urine citrate is important, being 
requested by urologists, to assess the risk of further stone 
formation and the benefit of the treatment. Kavanag and 
his group [28] developed a simple and rapid liquid 
chromatography tandem mass spectrometry (LC-MS/ MS) 
method, for the analysis of urinary citrate, and compared 
it with a current enzymatic assay. For the LC-MS/MS 
assay, samples were prepared in a deep-well block by 
adding 10 mL of urine and 20 mL of internal standard to 
400 mL of water. After the mixing, 3 mL of the diluted 
sample was injected into the LC-MS/MS system. A LC 
system was used to isocratically elute a C18 column 
(50_2.1 mm) with 0.4 mL/min water, containing 2 mmol/L 
ammonium acetate and 0.1% (v/v) formic acid. A step 
gradient of 100% methanol containing 2 mmol/L 
ammonium acetate and 0.1% (v/v) formic acid was used 
to wash the column. The retention times were 1.4 min for 
citrate and 1.4 min for d4-citrate. The cycle time was of 
4.0 min, injection to injection. The analytes were 
monitored by using a tandem mass spectrometer, which 
operated in multiple reaction monitoring mode by using 
the following transitions, citrate m/z 191.00>111.0 and d4-
citrate m/z 195.0>113.0 [ 28]. 
Many clinical and epidemiological studies relate 
hyperuricosuria to calcium oxalate stone formation. Uric 
acid crystals have crystallographic features similar to 
calcium oxalate monohydrate (COM) crystals, and for this 
reason, they act as active inducers of COM 
heterogeneous nucleation. Consequently, this fact would 
explain the physicochemical mechanism by which uric 
acid affects calcium oxalate crystallization. In spite of 
these facts, calcium oxalate/uric acid mixed calculi are not 
very common, corresponding to only 2.6% of all renal 
calculi. Costa-Bauza & all [29] evaluated the presence of 
uric acid in the beginning zone of different types of ‘pure’ 
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calcium oxalate renal calculi with the aim of establishing 
the degree of participation of uric acid crystals in the 
formation of such calculi. For this, the core or fragment of 
different types of ‘pure’ calcium oxalate renal calculi was 
detached, pulverized and uric acid extracted. Uric acid 
was determined by using HPLC-MS (high-performance 
liquid chromatography/mass spectrometry). 
Chromatographic separations were performed on an 
anion exchange resin. Mass spectral identification of uric 
acid was carried out with an electrospray ionization 
interface and a quadrupole mass analyzer. The mobile 
phase was nebulized by nitrogen gas at 350°C, with a 
flow rate of 13 L/min, into an electrospray mass analyzer. 
The detector counted negative ions with selected ion 
monitor (SIM) mode, by monitoring m/z = 167.1, which 
corresponds to the urate anion, the most abundant ion. If 
the papillary calculi with a core, are constituted by COM 
crystals and organic matter in calcium oxalate 
monohydrate (COM), then the concentration of uric acid is 
of 0.030 ± 0.007%. Moreover, 0.031 ± 0.008% uric acid 
was found in COM papillary calculi with a core constituted 
by hydroxyapatite. 0.24 ± 0.09% uric acid was found in 
COM unattached calculi (formed in renal cavities) with the 
core mainly formed by COM crystals and organic matter. 
20.8 ± 7.8% uric acid was found in COM unattached 
calculi with the core formed by uric acid identifiable by 
scanning electron microscopy (SEM), coupled to X-ray 
microanalysis. 0.012 ± 0.004% uric acid was found in 
calcium oxalate dihydrate (COD) unattached calculi 
containing little amounts of organic matter. 0.0030 ± 
0.0004% of uric acid was found in COD unattached calculi 
containing little amounts of organic matter and 
hydroxyapatite. From these results, the authors 
demonstrated that uric acid can play an important role as 
inducer (heterogeneous nucleant) of COM unattached 
calculi, with the core formed by uric acid identifiable by 
SEM, coupled to X-ray microanalysis (these calculi 
constitute the 1.2% of all calculi), as well as in COM 
unattached calculi, with the core mainly formed by COM 
crystals and organic matter (these calculi constitute the 
10.8% of all calculi) [29]. 
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